van Hellemond IEG, et al. - In this planned side-study, researchers evaluated treatment and detection of osteopenia/osteoporosis in terms of care patterns, as well as trends in bone mineral density (BMD) during and after treatment with adjuvant anastrozole (6 vs 3 year) in postmenopausal women with breast cancer enrolled in the phase 3 DATA study and formerly treated with 2-3 years of tamoxifen. All BMD measurements and bisphosphonate-use were assessed. Using Kaplan Meier methodology, they assessed time to osteopenia/osteoporosis. They used linear mixed models with random patients effects in order to study the trend in T-scores. This study included 1,860 eligible DATA patients, with a baseline BMD measurement available in 910 (48.9%). Findings revealed no association between extended anastrozole therapy and a higher incidence of osteoporosis. A modest BMD decrease was noted in relation to anastrozole use, but following anastrozole cessation, the decline somewhat reversible.